These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Packard KA; Campbell JA; Knezevich JT; Davis EM Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457 [TBL] [Abstract][Full Text] [Related]
5. The state of periprocedural antiplatelet therapy after recent trials. Desai NR; Bhatt DL JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450 [TBL] [Abstract][Full Text] [Related]
6. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome. Tan GM; Lam YY; Yan BP Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998 [TBL] [Abstract][Full Text] [Related]
7. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome. Dash D Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659 [TBL] [Abstract][Full Text] [Related]
9. Antiplatelet drugs: which targets for which treatments? Gachet C J Thromb Haemost; 2015 Jun; 13 Suppl 1():S313-22. PubMed ID: 26149041 [TBL] [Abstract][Full Text] [Related]
10. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Abergel E; Nikolsky E Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581 [TBL] [Abstract][Full Text] [Related]
11. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303 [TBL] [Abstract][Full Text] [Related]
12. New anti-platelet agents: the end of resistance? Kastrati A Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663 [TBL] [Abstract][Full Text] [Related]
13. New antiplatelet therapies in development. Price MJ Am J Health Syst Pharm; 2008 Jul; 65(13 Suppl 5):S11-5; quiz S16-8. PubMed ID: 18574020 [TBL] [Abstract][Full Text] [Related]
14. Evolving role of platelet function testing in coronary artery interventions. Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653 [TBL] [Abstract][Full Text] [Related]
16. Current options in oral antiplatelet strategies during percutaneous coronary interventions. Tantry US; Gurbel PA Rev Cardiovasc Med; 2011; 12 Suppl 1():S4-13. PubMed ID: 22080986 [TBL] [Abstract][Full Text] [Related]
17. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S; Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610 [TBL] [Abstract][Full Text] [Related]
18. Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Laine M; Camoin-Jau L; Bessereau J; Sébastien A; Paganelli F; Bonello L Curr Pharm Des; 2012; 18(33):5392-401. PubMed ID: 22724420 [TBL] [Abstract][Full Text] [Related]
19. Development and clinical use of prasugrel and ticagrelor. Ahmad S; Storey RF Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412 [TBL] [Abstract][Full Text] [Related]
20. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice? Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]